We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novavax’s COVID-19 Vaccine Candidate Gets FDA Fast Track Status
Novavax’s COVID-19 Vaccine Candidate Gets FDA Fast Track Status
As Novavax gears up to put its investigational COVID-19 vaccine through a phase 3 U.S. trial this month, the FDA has granted the candidate a Fast-Track designation in order to speed up its regulatory review process.